AR045811A1 - 5- arilpirimidinas como agentes ainticancerigenos - Google Patents

5- arilpirimidinas como agentes ainticancerigenos

Info

Publication number
AR045811A1
AR045811A1 ARP040103441A ARP040103441A AR045811A1 AR 045811 A1 AR045811 A1 AR 045811A1 AR P040103441 A ARP040103441 A AR P040103441A AR P040103441 A ARP040103441 A AR P040103441A AR 045811 A1 AR045811 A1 AR 045811A1
Authority
AR
Argentina
Prior art keywords
alkyl
mammal
compounds
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
ARP040103441A
Other languages
English (en)
Spanish (es)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR045811A1 publication Critical patent/AR045811A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP040103441A 2003-09-24 2004-09-23 5- arilpirimidinas como agentes ainticancerigenos AR045811A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50548703P 2003-09-24 2003-09-24

Publications (1)

Publication Number Publication Date
AR045811A1 true AR045811A1 (es) 2005-11-16

Family

ID=34393022

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103441A AR045811A1 (es) 2003-09-24 2004-09-23 5- arilpirimidinas como agentes ainticancerigenos

Country Status (24)

Country Link
US (1) US7524849B2 (enExample)
EP (1) EP1663241B1 (enExample)
JP (1) JP2007506746A (enExample)
KR (1) KR20060089215A (enExample)
CN (1) CN1871009A (enExample)
AR (1) AR045811A1 (enExample)
AT (1) ATE432077T1 (enExample)
AU (1) AU2004275733A1 (enExample)
BR (1) BRPI0414736A (enExample)
CA (1) CA2539235A1 (enExample)
CO (1) CO5690592A2 (enExample)
DE (1) DE602004021269D1 (enExample)
EC (1) ECSP066457A (enExample)
GT (1) GT200400188A (enExample)
IL (1) IL174305A0 (enExample)
MX (1) MXPA06003207A (enExample)
NO (1) NO20061319L (enExample)
PA (1) PA8613201A1 (enExample)
PE (1) PE20050470A1 (enExample)
RU (1) RU2006107578A (enExample)
SA (1) SA04250303A (enExample)
TW (1) TW200512198A (enExample)
WO (1) WO2005030216A1 (enExample)
ZA (1) ZA200602386B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200637556A (en) * 2005-01-31 2006-11-01 Basf Ag Substituted 5-phenyl pyrimidines I in therapy
CN101193884A (zh) 2005-06-13 2008-06-04 惠氏公司 微管蛋白抑制剂和其制备方法
JP2008543838A (ja) * 2005-06-13 2008-12-04 ワイス チューブリンインヒビターおよびその調製のためのプロセス
EP2001298A2 (de) * 2006-03-27 2008-12-17 Basf Se Substituierte 5-hetaryl-4-aminopyrimidine
CL2007002231A1 (es) * 2006-08-02 2008-04-11 Basf Ag Uso de compuestos derivados de 5-(het) arilpirimidina para combatir hongos daninos; compuestos derivados de 5-(het) arilpirimidina; agente fungicida; y agente farmaceutico.
WO2008084081A2 (en) * 2007-01-11 2008-07-17 Basf Se 2-substituted 5-phenylpyrimidines for the treatment of proliferative disorders
WO2009007187A1 (de) * 2007-07-09 2009-01-15 Basf Se Substituierte 5-hetarylpyrimidine
TWI548621B (zh) 2011-04-22 2016-09-11 標誌製藥公司 經取代之二胺基甲醯胺及二胺基甲腈嘧啶、其組合物、及以該等治療之方法
EP3219207A1 (en) * 2012-09-19 2017-09-20 The Trustees Of The University Of Pennsylvania Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
EP3712134B1 (en) 2014-12-16 2023-11-29 Signal Pharmaceuticals, LLC Salts of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
US9513297B2 (en) 2014-12-16 2016-12-06 Signal Pharmaceuticals, Llc Methods for measurement of inhibition of c-Jun N-terminal kinase in skin
EP3250557B1 (en) 2015-01-29 2024-11-20 Signal Pharmaceuticals, LLC Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
EP3325432B1 (en) 2015-07-24 2020-09-02 Celgene Corporation Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
WO2019169111A1 (en) 2018-03-02 2019-09-06 The Trustees Of The University Of Pennsylvania [1,2,4]triazolo[1,5-a]pyrimidine compounds and use in stabilizing microtubules
EP4052759A4 (en) * 2019-11-01 2023-12-20 Unimatec Co., Ltd. FLUORINE-CONTAINING PYRIMIDINE COMPOUND AND METHOD FOR THE PRODUCTION THEREOF
TW202132285A (zh) * 2019-11-13 2021-09-01 美商愛彼特生物製藥股份有限公司 經取代異吲哚啉基2,2’-聯嘧啶基化合物、其類似物及使用其之方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US116429A (en) * 1871-06-27 Improvement in dial-telegraph apparatus
US69242A (en) * 1867-09-24 Calvin pepper
US61889A (en) * 1867-02-05 Improvement in animal teaps
US88096A (en) * 1869-03-23 t h a y e r
US147744A (en) * 1874-02-24 Improvement in locomotive-furnaces
GB9700664D0 (en) 1997-01-14 1997-03-05 British Tech Group Anti-cancer agents
US6117876A (en) 1997-04-14 2000-09-12 American Cyanamid Company Fungicidal trifluorophenyl-triazolopyrimidines
AU3536699A (en) 1998-04-27 1999-11-16 Ihara Chemical Industry Co. Ltd. 3-arylphenyl sulfide derivatives and insecticides and miticides
US6156925A (en) 1998-09-25 2000-12-05 American Cyanamid Company Process for the preparation of halogenated phenylmaloates
US5986135A (en) 1998-09-25 1999-11-16 American Cyanamid Company Fungicidal trifluoromethylalkylamino-triazolopyrimidines
PL362551A1 (en) * 2000-06-13 2004-11-02 Basf Aktiengesellschaft Fungicidal 5-phenyl substituted 2-(cyanoamino) pyrimidines
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
SK11422003A3 (sk) * 2001-03-15 2004-04-06 Basf Aktiengesellschaft 5-Fenylpyrimidíny, spôsoby a medziprodukty na ich prípravu a ich použitie pri ničení škodlivých húb
ATE297390T1 (de) 2001-04-20 2005-06-15 Ciba Sc Holding Ag 4-amino-2-(2-pyridinyl)pyrimidine als mikrobizide wirksubstanzen
JP4450625B2 (ja) 2001-11-19 2010-04-14 ビーエーエスエフ ソシエタス・ヨーロピア 5−フェニルピリミジン類、その製造方法、これらを含む組成物及びこれらの使用
EP1504001B1 (de) 2002-02-21 2009-04-15 Basf Se 2-(2-pyridyl)-5-phenyl-6-aminopyrimidine, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen
AU2003214110A1 (en) 2002-03-15 2003-09-29 Ciba Specialty Chemicals Holding Inc. 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces
DK2316831T3 (da) 2002-11-21 2013-06-10 Novartis Ag 2-(Morpholin-4-yl)pyrimidiner som phosphotidylinositol (PI)-3-kinaseinhibitorer samt deres anvendelse ved behandling af cancer

Also Published As

Publication number Publication date
MXPA06003207A (es) 2006-06-23
KR20060089215A (ko) 2006-08-08
IL174305A0 (en) 2008-02-09
CA2539235A1 (en) 2005-04-07
ZA200602386B (en) 2009-03-25
WO2005030216A1 (en) 2005-04-07
DE602004021269D1 (de) 2009-07-09
EP1663241A1 (en) 2006-06-07
CN1871009A (zh) 2006-11-29
RU2006107578A (ru) 2007-10-27
US7524849B2 (en) 2009-04-28
SA04250303A (ar) 2005-12-03
EP1663241B1 (en) 2009-05-27
TW200512198A (en) 2005-04-01
JP2007506746A (ja) 2007-03-22
PE20050470A1 (es) 2005-10-03
NO20061319L (no) 2006-04-20
ECSP066457A (es) 2006-09-18
CO5690592A2 (es) 2006-10-31
US20050075357A1 (en) 2005-04-07
ATE432077T1 (de) 2009-06-15
BRPI0414736A (pt) 2006-11-21
GT200400188A (es) 2005-05-02
PA8613201A1 (es) 2005-11-25
AU2004275733A1 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
JP2008535902A5 (enExample)
MX2023006145A (es) Inhibidores de prmt5 novedosos.
IL261852A (en) Substituted imidazole based compounds for treatment of cancer
RU2015143542A (ru) Ингибиторы jak2 и alk2 и способы их использования
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
RU2013112871A (ru) Соединения для лечения рака
RU2016118753A (ru) Производные пиридилкетона, способ их получения и их фармацевтическое применение
RU2011150250A (ru) Антагонисты пути hedgehog и их терапевтическое применение
RU2014115847A (ru) Пирролопиримидиновые соединения для лечения злокачественной опухоли
JP2014503567A5 (enExample)
RU2011124304A (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2013538213A5 (enExample)
JP2014505660A5 (enExample)
CA2626032A1 (en) Camptothecin derivatives as chemoradiosensitizing agents
CN110769837A (zh) 与五氮杂大环状环配合物的联合癌症免疫疗法
CY1123161T1 (el) Παραγωγα δι(φαινυλοπροπανοειδους) γλυκερολης για τη θεραπεια του καρκινου
RU2013136861A (ru) Новое производное индола или индазола или его соль
JP2017503753A5 (enExample)
TW200512198A (en) 5-arylpyrimidines as anticancer agents
IS5588A (is) Æxliseyðandi miðlar
TW200512211A (en) 6-[(substituted)phenyl]triazolopyrimidines as anticancer agents
EA200701780A1 (ru) Противоопухолевое средство
WO2016205460A4 (en) Polycyclic derivatives targeting ral gtpases and their therapeutical applications
RU2017133419A (ru) Производные пиримидина в качестве ингибиторов киназы и их терапевтические применения

Legal Events

Date Code Title Description
FA Abandonment or withdrawal